Skip to main content
Clinical Trials/NCT01557179
NCT01557179
Completed
Phase 2

Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness. A Multicenter, Randomized, Controlled, Open-label, Parallel-group, Clinical Trial

Lee's Pharmaceutical Limited0 sites144 target enrollmentStarted: May 2009Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
Lee's Pharmaceutical Limited
Enrollment
144
Primary Endpoint
percentage of improvement of vaginal dryness symptoms

Overview

Brief Summary

This multicenter, randomized, controlled, open-label, parallel-group, 30-day study took place at four centers in China. The primary objective of this study was to assess the efficacy and safety of hyaluronic acid vaginal gel in treating vaginal dryness. In the current study we tested the hypothesis that the efficacy of hyaluronic acid vaginal gel was not inferior to that of estriol cream, with no clinically significant difference between them, in the treatment of vaginal dryness symptoms.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
25 Years to 70 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • under 70 years old,
  • had been naturally or surgically postmenopausal for more than 6 months,
  • had symptoms of vaginal dryness due to various causes and had no contraindications to locally applied estrogen

Exclusion Criteria

  • unmarried, pregnant and breast-feeding women,
  • patients with vaginal infections such as trichomonas,
  • candida and bacterial vaginosis,
  • patients with breast cancer, uterine cancer or estrogen hormone dependent tumors,
  • genital bleeding of unknown origin,
  • patients with acute hepatopathy, embolic disorders,
  • severe primary disease of the kidney and hematopoietic system
  • recent malignant tumors

Outcomes

Primary Outcomes

percentage of improvement of vaginal dryness symptoms

Time Frame: 30 days

percentage of improvement of vaginal dryness symptoms at the baseline and after treatment

Secondary Outcomes

  • percentage of improvement of itching, dyspareunia and burning sensation(30 days)

Investigators

Sponsor
Lee's Pharmaceutical Limited
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials